Healio Rheumatology


The following articles appeared in the print edition of HEALIO RHEUMATOLOGY.

Table of Contents
Cover Story

Mindset Matters: Harnessing the Placebo Effect for Patient Benefit

Drug Pipeline

FDA Approves Secukinumab Label Update for Dosing Flexibility in AS

FDA Grants Orphan Drug Status to IV Immunoglobulin Treatment for Systemic Sclerosis


Embracing the Placebo Effect: The Time has Arrived for Rheumatology

Leonard H. Calabrese, DO

Education Lab

Giant Cell Arteritis Curbside Consults: Patient Presenting to the Emergency Department With New-Onset Visual Symptoms


Diagnosis Detective: Discerning Vasculitis From its Many Mimics


Updated EULAR Recommendations for RA Allow Larger Role for JAK Inhibitors

Health Care Legislative and Regulatory Update

Trump’s Claim to have ‘Saved’ Pre-existing Conditions Clashes With Record

In the Journals

Less Than 40% of Patients With High RA Disease Activity Modify Treatment

Patients, Caregivers Weigh Disease, Treatment Risks When Deciding to End JIA Therapy

Abatacept Linked to Major Clinical RA Response in Men, Biologic-naive

Neuropsychiatric Events Most Frequent Near SLE Diagnosis, Linked to Excess Mortality

Patients With RA Skeptical of Patient-reported Outcome Measures

Physicians Should Counsel Patients on Safe Use of Cannabis Edibles

Symptomatic, Radiographic Knee OA Linked to Increased Mortality Risk

Tofacitinib Linked to Twofold Greater Risk for Herpes Zoster in RA

Two-thirds of Patients With PsA Waited 6 Months or More for Diagnosis

Patients With Moderate PsA Disease More Likely to Meet Treatment Targets With Apremilast

Optimal RA Management Reduces Risk for Adverse Pregnancy Outcomes

Meeting News

Head-to-head Trials Open New Data in PsA With ‘Cautionary’ Interpretation

Failure to ‘Move the Needle’ in OA Driving Joint Replacement Boom

Daytime-only NSAID Dosing May Foster Improved Healing, Recovery

As Shortage Looms, Tele-rheumatology Offers Solutions, Novel Legal Risks

Alternative Therapies Offer Mild Benefit, ‘Lousy Data’ for OA


APS Foundation of America Takes Aim at the Antiphospholipid Knowledge Gap

Trend Watch

FDA Approves Voltaren Arthritis Pain for Nonprescription, OTC Use

Cost Savings From Infliximab Biosimilars ‘Insufficient’ to Promote Use in US

ACR, Seven Medical Societies Warn BlueCross BlueShield Against New In-office Treatment Policy

FDA, Federal Trade Commission to Target ‘Anti-competitive’ Practices to Support Biosimilars